SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
=== World War II and the integration of treatment === When World War II broke out, the military once again called upon clinical psychologists. As soldiers began to return from combat, psychologists started to notice symptoms of psychological trauma labeled "shell shock" (eventually to be termed post-traumatic stress disorder) that were best treated as soon as possible. Because physicians (including psychiatrists) were over-extended in treating bodily injuries, psychologists were called to help treat this condition. At the same time, female psychologists (who were excluded from the war effort) formed the National Council of Women Psychologists with the purpose of helping communities deal with the stresses of war and giving young mothers advice on child rearing. After the war, the Veterans Administration in the US made an enormous investment to set up programs to train doctoral-level clinical psychologists to help treat the thousands of veterans needing care. As a consequence, the US went from having no formal university programs in clinical psychology in 1946 to over half of all PhDs in psychology in 1950 being awarded in clinical psychology. WWII helped bring dramatic changes to clinical psychology, not just in America but internationally as well. Graduate education in psychology began adding psychotherapy to the science and research focus based on the 1947 scientist-practitioner model, known today as the Boulder Model, for PhD programs in clinical psychology.
=== Other research === Recently there has been some research to identify potential antimicrobial peptides from prokaryotes, aquatic organisms such as fish, and shellfish, and monotremes such as echidnas.
Nonetheless, in July 2026, the Drug Enforcement Administration (DEA) announced its intention to temporarily make SR-17018 a Schedule I controlled substance in the United States under emergency scheduling protocols, with this announcement receiving opposition.
In October 2023, Hamas launched a surprise attack on Israel that devolved into an intensified conflict, jeopardizing the administration's push to normalize relations between Israel and Saudi Arabia. Biden stated his unequivocal support for Israel and condemned the attack by Hamas, but discouraged Israel from initiating a ground invasion of Gaza. Upon Israel's retaliation against Hamas, Biden deployed aircraft carriers in the region to deter others from joining the war, and called for an additional $14 billion in military aid to Israel. He later began pressuring Israel to address the growing humanitarian crisis in the Gaza Strip. Biden rejected calls for a ceasefire but said he supported "humanitarian pauses" to deliver aid to the Gaza Strip. He asked Israel to pause its invasion of Gaza for at least three days to allow for hostage negotiations; Israel agreed to daily four-hour pauses. He also directed the U.S. military to facilitate the delivery of humanitarian aid to Palestinians in Gaza. Biden has said he is a Zionist. He has faced criticism for his unwavering support for Israel. Officials have urged him to take a harder stance against Israel, criticizing his administration's leniency and support despite the Israeli government's contentious offensive, which has led to significant civilian casualties and humanitarian crises. Following the killing of Palestinian civilians receiving food aid on February 29, 2024, Biden said the current level of aid flowing into Gaza was insufficient. On March 3, the U.S. military began airdropping food aid into Gaza.
Sources: en.wikipedia.org
Vision loss can occur and is associated with strabismus, refractive errors, and anisometropia. It can also be caused by severely dry eyes, a consequence of lower eyelid abnormalities and frequent eye infections. Although an abnormally shaped skull is not distinctive for Treacher Collins syndrome, brachycephaly with bitemporal narrowing is sometimes observed. Cleft palate is also common. Dental anomalies are seen in 60% of affected people, including tooth agenesis (33%), discoloration (enamel opacities) (20%), malplacement of the maxillary first molars (13%), and wide spacing of the teeth. In some cases, dental anomalies in combination with mandible hypoplasia result in a malocclusion. This can lead to problems with food intake and the ability to close the mouth. Less common features of TCS may add to an affected person's breathing problems, including sleep apnea. Choanal atresia or stenosis is a narrowing or absence of the choanae, the internal opening of the nasal passages, which may also be observed. Underdevelopment of the pharynx can also narrow the airway. Features related to TCS that are seen less frequently include nasal deformities, high-arched palate, macrostomia, preauricular hair displacement, cleft palate, hypertelorism, notched upper eyelid, and congenital heart defects. Although facial deformity is often associated with developmental delay and intellectual disability, more than 95% of people affected with TCS have normal intelligence. The psychological and social problems associated with facial deformity can affect quality of life in individuals with TCS.
=== Asymmetric catalysis === Several strategies exist for constructing homochiral MOFs. Crystallization of homochiral MOFs via self-resolution from achiral linker ligands is one of the way to accomplish such a goal. However, the resulting bulk samples contain both enantiomorphs and are racemic. Aoyama and coworkers successfully obtained homochiral MOFs in the bulk from achiral ligands by carefully controlling nucleation in the crystal growth process. Zheng and coworkers reported the synthesis of homochiral MOFs from achiral ligands by chemically manipulating the statistical fluctuation of the formation of enantiomeric pairs of crystals. Growing MOF crystals under chiral influences is another approach to obtain homochiral MOFs using achiral linker ligands. Rosseinsky and coworkers have introduced a chiral coligand to direct the formation of homochiral MOFs by controlling the handedness of the helices during the crystal growth. Morris and coworkers utilized ionic liquid with chiral cations as reaction media for synthesizing MOFs, and obtained homochiral MOFs. The most straightforward and rational strategy for synthesizing homochiral MOFs is, however, to use the readily available chiral linker ligands for their construction.
Despite the signing of the Treaty of Peace and Friendship, Colon Freemasonry was still fundamentally divided between Eastern and Western Cuba and their cultural epicentres of Havana and Santiago de Cuba. José Fernández Pellón y Castellanos, leader of the Havana movement of Colon Freemasonry, entered into negotiations to relocate the Grand Lodge of Colon to Havana. He represented the interests of 27 Lodges in Western Cuba, all desiring that the Grand Lodge make the move. Soon after, the Grand Lodge of Colon did move to Havana, but the Supreme Council remained in Santiago de Cuba. On July 20, 1877, the Grand Lodge of Colon was officially reestablished in Havana, under Grand Master was Antonio Govín y Torres. The Masonic Lodges in their umbrella allowed for peaceful dialogues between Spanish reformists and Cuban pro-independence advocates. Several of the Colon Blue Lodges in Eastern Cuba did not agree with the decision. In 1877, some former members of the Grand Lodge of Colon at Santiago de Cuba established a second Grand Lodge of Colon at Havana. From 1877 to 1879, there were three Grand Lodges in Cuba operating simultaneously, all making the claim to be the "Regular" Grand Lodge.
=== Germany === In Germany, postgraduate medical training leading to specialization is generally referred to as Facharztweiterbildung. After obtaining the required authorization to practise medicine, physicians can apply for positions in approved hospitals and training institutions and complete specialist training while working under supervision. For international medical graduates, the pathway typically involves recognition of their medical qualifications, fulfilment of language requirements, and the applicable medical licensing process.
Desmethylprodine or 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP, Ro 2-0718) is an opioid analgesic drug developed in the 1940s by researchers at Hoffmann-La Roche. Desmethylprodine has been labeled by the DEA as a Schedule I drug in the United States. It is an analog of pethidine (meperidine), a Schedule II drug. Chemically, it is a reversed ester of pethidine which has about 70% of the potency of morphine. Unlike its derivative prodine, it does not exhibit optical isomerism. It was reported to have 30 times the activity of pethidine and a greater analgesic effect than morphine in rats, and it was demonstrated to cause central nervous system stimulation in mice.
Sources: en.wikipedia.org
Toxicodynamics (TD) and pharmacodynamics (PD) link a therapeutic agent or toxicant, or toxin (xenobiotic)'s dosage to the features, amount, and time course of its biological action. The mechanism of action is a crucial factor in determining effect and toxicity of the drug, taking in consideration the pharmacokinetic (PK) factors. The sort and extent of altered cellular physiology will depend on the combination of the drug's presence (as established by pharmacokinetic (PK) studies) and/or its mechanism and duration of action (PD). Types of xenobiotic-target interaction can be described either by reversible, irreversible, noncompetitive, and allosteric interaction or agonist, partial agonist, antagonist, and inverse interactions. In vitro, ex vivo, or in vivo studies can be used to assess PD and TD from the molecule to the level of the entire organism. The mechanism of drug action and adverse drug reaction is either physiochemical property based and biochemical based. Adverse drugs reactions can be classified as either idiosyncratic (type B) or intrinsic (type A). Idiosyncratic toxicity is not dosage dependent and defy the mass-action relationship. Immune-mediated processes are frequently cited as the source of type B reactions. These cannot be accurately described in preclinical research or clinical trials due to their low incidence frequency. Type A reactions are dosage (concentration) dependent. Usually, this kind of side effect is an extension of an ongoing treatment.
=== February === February 1 Oregon Measure 110 comes into effect, making Oregon the first state to decriminalize the possession of small quantities of all illicit drugs. Actress Evan Rachel Wood alleges that Marilyn Manson sexually abused and groomed her as a teenager. Four other women make similar claims while Manson denies the allegations. The next day, February 2, Manson is dropped by his record label, Loma Vista Recordings, and removed from two TV shows: American Gods and Creepshow. February 2 2021 Sunrise, Florida shootout: During the service of a warrant, a suspect kills two FBI agents and injures three others before barricading himself inside his home. He is later found dead, reportedly from a self-inflicted gunshot wound. The shootout was the most violent incident in the FBI's history since 1986. The United States Senate votes 50–49 to pass a budget resolution that would allow Democrats to pass President Biden's $1.9 trillion relief package without support from Republicans. Three days later, February 5, the Senate passes a $1.9 trillion budget for COVID-19 relief. The 50–50 tie-breaker vote is broken by Vice President Kamala Harris. Amazon founder and CEO Jeff Bezos steps down after more than 26 years to focus on Blue Origin and names Amazon Web Services CEO Andy Jassy as his successor.
=== Pore size === Many stationary phases are porous to provide greater surface area. Small pores provide greater surface area while larger pore size has better kinetics, especially for larger analytes. For example, a protein which is only slightly smaller than a pore might enter the pore but does not easily leave once inside.
=== Magnetic and Magnetoelectric nanoparticles === In contrast to the above mechanisms, a delivery with magnetic fields does not strongly depend on the biochemistry of the brain. In this case, nanoparticles are literally pulled across the BBB via application of a magnetic field gradient. The nanoparticles can be pulled in as well as removed from the brain merely by controlling the direction of the gradient. For the approach to work, the nanoparticles must have a non-zero magnetic moment and have a diameter of less than 50 nm. Both magnetic and magnetoelectric nanoparticles (MENs) satisfy the requirements. However, it is only the MENs which display a non-zero magnetoelectric (ME) effect. Due to the ME effect, MENs can provide a direct access to local intrinsic electric fields at the nanoscale to enable a two-way communication with the neural network at the single-neuron level. MENs, proposed by the research group of Professor Sakhrat Khizroev at Florida International University (FIU), have been used for targeted drug delivery and externally controlled release across the BBB to treat HIV and brain tumors, as well as to wirelessly stimulate neurons deep in the brain for treatment of neurodegenerative diseases such as Parkinson's Disease and others.
=== Mass spectrometry imaging === By continuously scanning a surface, such as tissue section, nano-DESI can be used for imaging. By carefully choosing the experimental conditions, such as the nano-DESI solvent, additives, and the ionization mode (positive or negative) we can map the distribution of a wide variety of complex molecules on different surfaces. A few examples to mention are proteins, lipids, small metabolites, drugs or even the distribution of endogenous alkali metals. Nano-DESI has been applied for localized analysis of complex molecules and imaging of tissue sections, microbial communities and environmental samples.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.